Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting the hallmarks of aging: mechanisms and therapeutic opportunities.

Frontiers in cardiovascular medicine·2025

Same author

A Role for Periostin Pathological Variants and Their Interaction with HSP70-1a in Promoting Pancreatic Cancer Progression and Chemoresistance.

International journal of molecular sciences·2024

Same author

Expression of Periostin Alternative Splicing Variants in Normal Tissue and Breast Cancer.

Biomolecules·2024

Same author

The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer.

Cells·2024

Same author

Experimental Study: The Development of a Novel Treatment for Chemotherapy-Resistant Tongue Cancer with the Inhibition of the Pathological Periostin Splicing Variant 1-2 with Exon 21.

Cells·2024

Same author

Blocking Periostin Prevented Development of Inflammation in Rhabdomyolysis-Induced Acute Kidney Injury Mice Model.

Cells·2022

Search research articles

Related Experiment Video

Updated: Dec 17, 2025

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Therapeutic Angiogenesis Using HGF Plasmid.

Fumihiro Sanada¹, Tatsuya Fujikawa¹, Kana Shibata¹

¹Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Annals of Vascular Diseases

|June 30, 2020

Summary

Hepatocyte growth factor (HGF) promotes blood vessel growth and reduces inflammation and fibrosis. Its therapeutic potential for peripheral artery disease, characterized by these conditions, is highlighted.

Keywords:

HGF gene therapy peripheral artery disease

More Related Videos

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Experiment Videos

Last Updated: Dec 17, 2025

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Area of Science:

Regenerative Medicine
Molecular Biology
Cardiovascular Research

Background:

Hepatocyte growth factor (HGF) is secreted by stromal cells and binds to its receptor cMet on various cell types.
HGF stimulates cell proliferation, motility, and morphogenesis, playing a key role in angiogenesis.
HGF exhibits anti-inflammatory and anti-fibrotic properties, demonstrated in animal models.

Purpose of the Study:

To discuss the pleiotropic actions of HGF, distinguishing it from other angiogenic factors.
To review human clinical studies involving HGF gene therapy for therapeutic applications.

Main Methods:

Narrative review of existing literature on HGF.
Analysis of HGF's role in angiogenesis, inflammation, and fibrosis.
Overview of human clinical trial outcomes using HGF gene therapy.

Main Results:

HGF demonstrates multifaceted effects on ischemic tissues, including angiogenesis, inflammation reduction, and fibrosis regression.
Compared to other angiogenic factors, HGF offers a broader therapeutic profile.
Clinical studies suggest potential benefits of HGF gene therapy.

Conclusions:

HGF's unique combination of angiogenic, anti-inflammatory, and anti-fibrotic effects makes it a promising therapeutic agent.
HGF holds significant therapeutic potential for peripheral artery disease due to its ability to address chronic inflammation and fibrosis.
Gene therapy with HGF warrants further investigation for treating ischemic conditions.